Curcuminoid composition of curcumin-keto, method of preparation and use thereof
A composition for enhanced bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin, a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12-0.20:0.8-0.88. A composition for enhanced lymphatic bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin, a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12-0.20:0.8-0.88. Methods for making the composition for enhanced bioavailability of curcumin. Methods for making the composition for enhanced lymphatic bioavailability of curcumin.
1. A composition for enhanced bioavailability of curcumin in blood comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin and a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12-0.20:0.8-0.88, and wherein the composition is a free-flowing powder.
2. The composition for enhanced bioavailability of curcumin in blood of claim 1 , wherein the weight ratio for the curcumin-keto compound to the curcumin-enol compound is about 0.15: about 0.85.
3. The composition for enhanced bioavailability of curcumin in blood of claim 1 , wherein the essential oil of turmeric comprises ar-turmerone.
4. The composition for enhanced bioavailability of curcumin in blood of claim 1 , wherein the essential oil of turmeric comprises about 30% to about 60% ar-turmerone by weight.
5. The composition for enhanced bioavailability of curcumin in blood of claim 1 , wherein a weight ratio of the curcuminoid mixture to the essential of turmeric ranges from about 5:1 to about 20:1 by weight.
6. The composition for enhanced bioavailability of curcumin in blood of claim 1 , wherein the composition comprises a surface area ranging from about 0.05 to about 0.3 m 2 /g.
7. The composition for enhanced bioavailability of curcumin in blood of claim 5 , wherein the composition comprises a surface area of about 0.17 m 2 /g.
8. The composition for enhanced bioavailability of curcumin in blood of claim 1 comprising a scanning electron microscopy (SEM) image chosen from FIG. 5 B , FIG. 6 B , FIG. 7 B or FIG. 8 B .
9. The composition for enhanced bioavailability of curcumin in blood of claim 1 comprising a Fourier Transform Infrared Spectroscopy (FTIR) spectra as presented in FIG. 9 B .
10. The composition for enhanced bioavailability of curcumin in blood of claim 1 comprising a Nuclear Magnetic Resonance (NMR) spectra as presented in FIG. 10 B .
11. The composition for enhanced bioavailability of curcumin in blood of claim 1 comprising a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI TOF) spectra as presented in FIG. 11 B .
12. An oral dosage form comprising the composition for enhanced bioavailability of curcumin in blood of claim 1 chosen from tablet, capsule, soft gel capsule, granule, powder, lozenge, syrup, elixir, solution or suspension.
13. The composition for enhanced bioavailability of curcumin in blood of claim 1 prepared by a method, the method comprising:
suspending a curcuminoid mixture in about 10 to about 20 times water to form a suspension;
refluxing the suspension at about 70° C. to about 95° C. for about 0.5 hour to about 5 hrs to obtain a refluxed mixture;
evaporating water from the refluxed mixture under vacuum and at about 30° C. to about 60° C. till volume of the refluxed mixture is decreased to half to obtain an evaporated mixture;
adding essential oil of turmeric to the evaporated mixture to form a blend;
drying the blend under vacuum at about 30° C. to about 65° C. to obtain the composition for enhanced bioavailability of curcumin of claim 1 .
14. A composition for enhanced lymphatic bioavailability of curcumin comprising a curcuminoid mixture and an essential oil of turmeric, wherein the curcuminoid mixture comprises a curcumin-keto compound, a curcumin-enol compound, a bisdemethoxycurcumin and a demethoxycurcumin, wherein a weight ratio of the curcumin-keto compound to the curcumin-enol compound ranges from about 0.12-0.20:0.8-0.88, and wherein the composition is a free-flowing powder.
15. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 , wherein the weight ratio of the curcumin-keto compound to the curcumin-enol compound is about 0.15:0.85.
16. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 , wherein the composition comprises a surface area ranging from about 0.05 to about 0.3 m 2 /g.
17. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 , wherein the composition comprises a surface area of about 0.17 m 2 /g.
18. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 comprising a Scanning Electron Microscopy (SEM) image chosen from FIG. 5 B , FIG. 6 B , FIG. 7 B or FIG. 8 B .
19. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 comprising a Fourier Transform Infrared (FTIR) spectra as presented in FIG. 9 B .
20. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 comprising a Nuclear Magnetic Resonance (NMR spectra) as presented in FIG. 10 B .
21. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 comprising a Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI TOF) spectra as presented in FIG. 11 B .
22. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 , wherein the essential oil of turmeric comprises ar-turmerone.
23. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 , wherein the essential oil of turmeric comprises about 30% to about 60% ar-turmerone by weight.
24. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 , wherein a weight ratio of the curcuminoid mixture to the essential of turmeric ranges from about 5:1 to about 20:1 by weight.
25. An oral dosage form comprising the composition for enhanced lymphatic bioavailability of curcumin of claim 14 chosen from tablet, capsule, soft gel capsule, granule, powder, lozenge, syrup, elixir, solution or suspension.
26. The composition for enhanced lymphatic bioavailability of curcumin of claim 14 prepared by a method, the method comprising:
suspending a curcuminoid mixture in about 10 to about 20 times water to form a suspension;
refluxing the suspension at about 70° C. to about 95° C. for about 0.5 hour to about 5 hrs to obtain a refluxed mixture;
evaporating water from the refluxed mixture under vacuum and at about 30° C. to about 60° C. till volume of the refluxed mixture is decreased to half to obtain an evaporated mixture;
adding essential oil of turmeric to the evaporated mixture to form a blend;
drying the blend under vacuum at about 30° C. to about 65° C. to obtain the composition for enhanced lymphatic bioavailability of curcumin of claim 14 .